Therefore, in future multi-center clinical studies should be performed to explore the prognostic significance of IL-22 expression in HCC patients treated with sorafenib and its correlation with the expressions of STAT3 and CD155 in the tumor tissues collected from those patients to validate our conclusion. Here, IL22 is linked to neoplasm.